These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8603942)

  • 1. Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults.
    Powers DC; Anderson EL; Lottenbach K; Mink CM
    J Infect Dis; 1996 Apr; 173(4):1014-8. PubMed ID: 8603942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants.
    Ahman H; Käyhty H; Tamminen P; Vuorela A; Malinoski F; Eskola J
    Pediatr Infect Dis J; 1996 Feb; 15(2):134-9. PubMed ID: 8822286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infant immunization with pneumococcal CRM197 vaccines: effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines.
    Daum RS; Hogerman D; Rennels MB; Bewley K; Malinoski F; Rothstein E; Reisinger K; Block S; Keyserling H; Steinhoff M
    J Infect Dis; 1997 Aug; 176(2):445-55. PubMed ID: 9237711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
    McFetridge R; Meulen AS; Folkerth SD; Hoekstra JA; Dallas M; Hoover PA; Marchese RD; Zacholski DM; Watson WJ; Stek JE; Hartzel JS; Musey LK
    Vaccine; 2015 Jun; 33(24):2793-9. PubMed ID: 25913828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly.
    Sankilampi U; Honkanen PO; Bloigu A; Herva E; Leinonen M
    J Infect Dis; 1996 Feb; 173(2):387-93. PubMed ID: 8568300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants.
    Dagan R; Kayhty H; Wuorimaa T; Yaich M; Bailleux F; Zamir O; Eskola J
    Pediatr Infect Dis J; 2004 Feb; 23(2):91-8. PubMed ID: 14872172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The lack of association between aging and postvaccination levels of IgG antibody to capsular polysaccharides of Streptococcus pneumoniae.
    Musher DM; Groover JE; Graviss EA; Baughn RE
    Clin Infect Dis; 1996 Jan; 22(1):165-7. PubMed ID: 8824989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults.
    Shelly MA; Jacoby H; Riley GJ; Graves BT; Pichichero M; Treanor JJ
    Infect Immun; 1997 Jan; 65(1):242-7. PubMed ID: 8975918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumococcal capsular polysaccharide-meningococcal outer membrane protein complex conjugate vaccines: immunogenicity and efficacy in experimental pneumococcal otitis media.
    Giebink GS; Koskela M; Vella PP; Harris M; Le CT
    J Infect Dis; 1993 Feb; 167(2):347-55. PubMed ID: 8421168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of the 23-valent pneumococcal polysaccharide vaccine in Alaska Native chronic alcoholics compared with nonalcoholic Native and non-Native controls.
    McMahon BJ; Parkinson AJ; Bulkow L; Davidson M; Wainwright K; Wolfe P; Schiffman GS
    Am J Med; 1993 Dec; 95(6):589-94. PubMed ID: 8259775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial.
    Ahmed F; Steinhoff MC; Rodriguez-Barradas MC; Hamilton RG; Musher DM; Nelson KE
    J Infect Dis; 1996 Jan; 173(1):83-90. PubMed ID: 8537687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [An immunoenzymatic test for IgG antibody levels against 10 serotypes of Streptococcus pneumoniae].
    Leal-Esteban LC; Rojas JL; Jaimes AL; Montoya JD; Montoya NE; Leiva L; Trujillo-Vargas CM
    Biomedica; 2012; 32(1):92-102. PubMed ID: 23235791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and efficacy of Streptococcus pneumoniae polysaccharide-protein conjugate vaccines against homologous and heterologous serotypes in the chinchilla otitis media model.
    Giebink GS; Meier JD; Quartey MK; Liebeler CL; Le CT
    J Infect Dis; 1996 Jan; 173(1):119-27. PubMed ID: 8537648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of the American Academy of Pediatrics--recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients.
    Lin PL; Michaels MG; Green M; Mazariegos GV; Webber SA; Lawrence KS; Iurlano K; Greenberg DP
    Pediatrics; 2005 Jul; 116(1):160-7. PubMed ID: 15995047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher Cytokine and Opsonizing Antibody Production Induced by Bovine Serum Albumin (BSA)-Conjugated Tetrasaccharide Related to
    Kurbatova EA; Akhmatova NK; Zaytsev AE; Akhmatova EA; Egorova NB; Yastrebova NE; Sukhova EV; Yashunsky DV; Tsvetkov YE; Nifantiev NE
    Front Immunol; 2020; 11():578019. PubMed ID: 33343566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Tdap when administered before, with or after the 13-valent pneumococcal conjugate vaccine (coadministered with the quadrivalent meningococcal conjugate vaccine) in adults: A randomised controlled trial.
    Tashani M; Alfelali M; Barasheed O; Alqahtani AS; Heron L; Wong M; Rashid H; Booy R
    Vaccine; 2016 Nov; 34(48):5929-5937. PubMed ID: 27780630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the immunogenicity and safety of polysaccharide and protein-conjugated pneumococcal vaccines among the elderly aged 80 years or older in Japan: an open-labeled randomized study.
    Namkoong H; Funatsu Y; Oishi K; Akeda Y; Hiraoka R; Takeshita K; Asami T; Yagi K; Kimizuka Y; Ishii M; Tasaka S; Suzuki Y; Iwata S; Betsuyaku T; Hasegawa N
    Vaccine; 2015 Jan; 33(2):327-32. PubMed ID: 25448102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.
    Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y
    Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial.
    Nakashima K; Aoshima M; Ohfuji S; Yamawaki S; Nemoto M; Hasegawa S; Noma S; Misawa M; Hosokawa N; Yaegashi M; Otsuka Y
    Hum Vaccin Immunother; 2018; 14(8):1923-1930. PubMed ID: 29561248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody responses to pneumococcal polysaccharide vaccine in Taiwanese patients with chronic obstructive pulmonary disease.
    Lai CC; Lee LN; Yu CJ; Hsueh PR; Yang PC; Kuo SH; Luh KT
    J Formos Med Assoc; 2007 Mar; 106(3):196-203. PubMed ID: 17389163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.